Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Therapeutic
- Drug Discovery
- Assay
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 240609
Licensed Compound shall mean a compound which is an Active Compound and which is recommended by the Research Committee and selected by Licensee for GLP Toxicology Studies and further development under the License Agreement.
Active Compound shall mean each Licensee or Licensor Substance which meets the criteria set forth (including any such Substance which was screened in Assays prior to the Effective Date and for which the Research Committee determines that such criteria are met), and each derivative or analogue thereof developed in the course of, but not after, the Research Program or the Tail End Period, if such derivative or analog thereof meets the criteria set forth.
The collaboration agreement is to discover and develop antibacterial drugs based on the two principal targets in the Licensor's anti-bacterial program.
IPSCIO Record ID: 298928
Licensor grants, during the Research Term, an exclusive, non-transferable license to use the Program Assays to screen the Program Substances in accordance with the Research Program and a nontransferable, non-exclusive license under the Licensor-owned Program Patents and the Licensor Technology other than the Program Assays to the extent necessary to screen the Program Substances against the Program Assays in accordance with the terms of the Research Program.
For the Preliminary Development by Licensee of Option-Compounds, Licensor grants to an exclusive license under the Licensor-owned and jointly owned Program Patents, the Licensor-owned and jointly owned Program Know-How and the LicensorTechnology for the limited purpose of conducting biological studies, medicinal chemistry, pharmacological development, preliminary animal safety studies or other pre-IND development activities with respect to any Option Compound within any Option Program.
Program Product shall mean any pharmaceutical product which results during the Research Term from research conducted with respect to a Program Compound. Each Program Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.
Option Compound shall mean a Program Substance which as a result of screening activities under the Research Program, reveals Anti-Viral Activity in only one or more Option Targets, which is not designated by Licensee as a Restricted Compound and as to which Licensor has commenced and is proceeding with preliminary development activities within two (2) years after the expiration of the Research Term.
— Option Product shall mean any pharmaceutical product which results during the Research Term or within two (2) years thereafter, from research conducted with respect to an Option Compound. Each Option Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.
— Option Program shall mean either the Herpes Simplex Virus Option Program or the Cytomegalovirus Option Program, as the case may be.
The Targets and Assays are
• Human Immunodeficiency Virus Integrase
• Human Immunodeficiency Virus Tat
• Hepatitis C Virus Helicase
The Core Target Assays are
• Human Immunodeficiency Virus Integrase
• Human Immunodeficiency Virus Tat
• Hepatitis C Virus Helicase
The Option Targets are
• Cytomegalovirus E2
• Herpes Simplex Virus HelicasePrimase
The Option Target Assays are
• Recombinant Cytomegalovirus
• Cytomegalovirus E2
• Recombinant Herpes Simplex Virus
• Herpes Simplex Virus HelicasePrimase
IPSCIO Record ID: 245952
The Licensor and the Japanese Licensee wish to develop and market novel therapeutic products based on compounds identified pursuant to the Collaboration Agreement. The amendment clarifies, Licensor will screen compounds to identify specific compounds having promising activity for lowering serum LDL-cholesterol through the regulation of CYP7 gene expression or through interaction with the nuclear hormone receptor LXRa.
In the License agreement, Licensor grants the Japanese Licensee the right and license, with the right to sublicense, to develop Preclinical Candidates and to make, have made, use and sell Products under the Licensor Technology and the Licensor-owned and jointly owned Program Technology. The license granted herein shall be exclusive, even as to Licensor, throughout the Licensees Territory.
Product shall mean any pharmaceutical product, including all formulations, line extensions or modes of administration thereof, for use within the Field, which contains an active ingredient which is or is derived from a Preclinical Candidate to this Agreement.
IPSCIO Record ID: 369401
(a) to Exploit (i) Ispronicline and Ispronicline Products (including conducting the Pre-Phase IIb Program), (ii) any Licensed Derivatives with respect to Ispronicline, and (iii) any Additional Compounds with respect to the foregoing;
(b) to Exploit (i) Collaboration Candidates and Active+ Compounds until such time, with respect to each such Collaboration Candidate and Active+ Compound, as it becomes a Terminated Compound, (ii) Collaboration Compounds, Candidate Drugs, and Products (other than Ispronicline or Ispronicline Products (or any Licensed Derivatives with respect thereto), Option Compound Candidate Drugs or Option Compound Products), and (iii) any Additional Compounds with respect to the foregoing; and
(c) to Exploit (i) Option Compound Candidate Drugs and Option Compound Products and (ii) any Additional Compounds with respect to the foregoing;
Product means a product that consists of or contains a Candidate Drug as an active ingredient.
Candidate Drug means each of (a) Ispronicline, (b) each Active+ Compound that is not a Terminated Compound, (c) each Collaboration Compound for which Licensee commences GLP Toxicology Studies as provided in Agreement or for which Licensee does not commence GLP Toxicology Studies but Initiates a Clinical Trial, (d) each Option Compound for which Licensee exercises an Option, (e) each Licensed Derivative with respect to (i) any such Option Compound made by or on behalf of Licensee or its Affiliates or Sublicensees or (ii) Ispronicline or any such Active+ Compound or Collaboration Compound made by or on behalf of (A) Licensee, Licensor or any of their respective Affiliates or Sublicensees during the Research Program Term or the Tail Period or (B) Licensee, or its Affiliates or Sublicensees after the Tail Period and (f) in each case ((a) through (e)), any salt form, polymorph, crystalline form, hydrate, solvate or formulation thereof.
Compound means any compound Controlled by Licensor.
Licensor Patent Rights means any Patent Rights Controlled by Licensor or its Affiliates that contain one or more claims that cover (a) Licensor Technology, (b) any (i) Collaboration Candidate, Active+ Compound, Collaboration Compound, Candidate Drug or Product, (ii) Additional Compound or Derivative with respect to any of the foregoing, or (iii) product that contains any of the foregoing (including any Additional Product) or (c) the Exploitation of any of the foregoing ((a) and (b)) in the Field or in Schizophrenia.
Compound Family means (a) with respect to each Lead Collaboration Compound, such Lead Collaboration Compound, all Related Collaboration Compounds with respect to such Lead Collaboration Compound, and all Licensed Derivatives with respect to either of the foregoing, (b) with respect to Ispronicline, Ispronicline and all Licensed Derivatives with respect thereto, (c) with respect to each IND-Ready Option Candidate Drug, such IND-Ready Option Candidate Drug and all Licensed Derivatives with respect thereto and (d) with respect to each POC Option Candidate Drug, such POC Option Candidate Drug and all Licensed Derivatives with respect thereto.
Lead Collaboration Compound means each Active+ Compound that is selected by the JRC or Licensee, as a Lead Collaboration Compound during the Research Program Term or the Tail Period, including any salt form, polymorph, crystalline form, hydrate, solvate or formulation thereof. Notwithstanding anything in this Agreement to the contrary, in no event shall a Licensed Derivative with respect to Ispronicline be a Lead Collaboration Compound unless Licensee, designates it as a Lead Collaboration Compound pursuant to this agreement. For purposes of clarity, Ispronicline is not a Lead Collaboration Compound and, except as provided in the preceding sentence, Licensed Derivatives with respect to Ispronicline, even if Derived during the Research Program Term or the Tail Period, are not Lead Collaboration Compounds.
Option Compound means during the Option Term (and, if an IND-Ready Option Period or POC Option Period begins during the Option Term and has not expired as of the last day of the Option Term, thereafter until the last day of such IND-Ready Option Period or POC Option Period), any Secondary Pharmacology Compound or Other NNR Compound on which Licensor conducts research or development activities specifically for use in the Territory in the Field or, prior to the Schizophrenia Expiration Date, Schizophrenia and elects, in its sole discretion, to designate as an Option Compound. For purposes of clarity, (a) an Alpha4Beta2 Agonist shall not be an Option Compound, (b) an Unexercised Option Compound shall, upon becoming an Unexercised Option Compound, cease to be an Option Compound, (c) a Terminated Compound that was previously an Option Compound shall, upon becoming a Terminated Compound, cease to be an Option Compound and (d) an Excluded Zone Compound shall not be an Option Compound.
Ispronicline Product means any Product that contains Ispronicline as an active ingredient. For purposes of clarity, an Ispronicline Product is also a Product.
Field means the treatment, prevention or diagnosis of Primary Indications and Small Market Indications in humans or animals including Schizophrenia.
Schizophrenia means a condition having the diagnostic criteria for schizophrenia identified in DSM-IV, ICD-10 or any other Diagnostic Manual, but excluding CDS. When used as reference to a field (as distinguished from an indication), Schizophrenia means the treatment, prevention or diagnosis of such a condition.
Small Market Indication means each of the following (a) Vascular Dementia; (b) Dementia due to HIV; (c) Dementia due to head trauma; (d) Dementia due to Parkinson’s disease; (e) Dementia due to Huntington’s disease; (f) Dementia due to Pick’s disease; and (g) Dementia due to Creutzfeldt-Jakob disease; (h) Dementia due to other general medical conditions (including Dementia with Lewy Bodies); (i) substance induced Dementia; (j) Dementia due to multiple etiologies; in each case ((a) through (j)) based on diagnostic criteria included in DSM-IV, ICD-10 or any other Diagnostic Manual; (k) any Newly-Defined Cognitive Disorder or Associated Cognitive Impairment; provided that, in the case of (h) through (k), only if such Dementia, Newly-Defined Cognitive Disorder or Associated Cognitive Impairment has a patient population in the United States of 200,000 or less based on the findings of such pharmaceutical market research organization(s) as Licensee may designate from time to time with Licensor’s consent, not to be unreasonably withheld, conditioned or delayed; and (l) any Additional Small Market Indication. For purposes of clarity, Schizophrenia is not a Small Market Indication.
IPSCIO Record ID: 293995
Licensor grants to Merck, during the Research Term an exclusive, non-transferable license to use the Program Assays to screen the Program Substances in accordance with the terms of the Research Program; and a non-exclusive, nontransferable license under Licensor-owned Program Patents and the Licensor Technology other than the Program Assays, to the extent necessary to screen the Program Substances in accordance with the terms of the Research Program.
For the Preliminary Development by Licensee of Program Compounds. Licensor grants an exclusive license under the Licensor-owned and jointly owned Program Patents, the Licensor owned and jointly owned Program Know-How and the Licensor Technology for the limited purpose of conducting biological studies, medicinal chemistry, pharmacological development, preliminary animal studies or such other pre-IND development activities as are necessary for Licensee to fulfill its obligations under the Research Program.
For the License to Licensee for Program Products, Licensor grants an exclusive, worldwide license to develop, make, have made, use, sell and have sold Program Products in the Field under the Licensor-owned and jointly owned Program Patents, the Licensor-owned and jointly owned Program Know-How and the Licensor Technology.
Licensee shall have the exclusive right to develop and commercialize any Program Compound for applications outside the Field.
Program Product shall mean any pharmaceutical product which results during the Research Term from research conducted with respect to a Program Compound. Each Program Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.
Option Compound shall mean a Program Substance which as a result of screening activities under the Research Program, reveals Anti-Viral Activity in only one or more Option Targets, which is not designated by Licensee as a Restricted Compound and as to which Licensor has commenced and is proceeding with preliminary development activities within two (2) years after the expiration of the Research Term.
— Option Product shall mean any pharmaceutical product which results during the Research Term or within two (2) years thereafter, from research conducted with respect to an Option Compound. Each Option Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.
— Option Program shall mean either the Herpes Simplex Virus Option Program or the Cytomegalovirus Option Program, as the case may be.
The Targets and Assays are
• Human Immunodeficiency Virus Integrase
• Human Immunodeficiency Virus Tat
• Hepatitis C Virus Helicase
The Core Target Assays are
• Human Immunodeficiency Virus Integrase
• Human Immunodeficiency Virus Tat
• Hepatitis C Virus Helicase
The Option Targets are
• Cytomegalovirus E2
• Herpes Simplex Virus HelicasePrimase
The Option Target Assays are
• Recombinant Cytomegalovirus
• Cytomegalovirus E2
• Recombinant Herpes Simplex Virus
• Herpes Simplex Virus HelicasePrimase
